In addition to utilising nanoparticles as immunoadjuvant to activate immune systems, Jie has also demonstrated that rationally designed nanoparticles are able to modulate the death modality of cancer cells in a manner that can alert immune systems and generate an anti-cancer adaptive immune response. The core technology is being further developed into an oral nanoformulation with improved safety profile for cancer recurrence prevention which holds high potential for clinical translation and attracted fundings from NHMRC.

Project members


Dr Jie Tang

NHMRC Emerging Leadership Fellow
Yu Group